This systematic review and meta-analysis will be conducted in accordance with the Preferred Reporting Items for Systematic Reviewd and Meta-Analyses 2020 statement. Moreover, we will search MEDLINE (via OVID), EMBASE and the Cochrane Library without any language and date restrictions. Observational studies will be included. Two reviewers will independently perform the entire procedure, and disagreements will be settled by discussion between them and consultation with a third reviewer. Standardised electronic forms will be generated to extract data. The risk of bias in the individual studies will be evaluated using the Newcastle-Ottawa scale. All statistical analyses will be performed using the RevMan software or the Stata software.
This study will include peer-reviewed published articles; thus, no ethical issues will be involved. Further, the final manuscript will be published in a peer-reviewed journal.
CRD42022380180.
方法:本系统综述和荟萃分析将根据2020年系统综述和荟萃分析的首选报告项目声明进行。此外,我们将搜索MEDLINE(通过OVID),EMBASE和Cochrane图书馆没有任何语言和日期限制。将包括观察性研究。两名评审员将独立执行整个过程,分歧将通过他们之间的讨论和与第三位审稿人协商来解决。将生成标准化的电子表格来提取数据。将使用纽卡斯尔-渥太华量表评估个体研究中的偏倚风险。所有统计分析将使用RevMan软件或Stata软件进行。
背景:这项研究将包括同行评审的已发表的文章;因此,不会涉及任何道德问题。Further,最终稿件将发表在同行评审的期刊上.
■CRD42022380180。